eFFECTOR Therapeutics Company Description
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer.
The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.
The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer.
eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Craig Jalbert |
Contact Details
Address: 142 North Cedros Avenue Solana Beach, Delaware 92075 United States | |
| Phone | 858 925 8215 |
| Website | effector.com |
Stock Details
| Ticker Symbol | EFTR |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US28202V1089 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | Chief Executive Officer, President, Treasurer &Secretary, and Director |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |